tbuckley/cabot-search huggingface dataset:
Trends of Venous Thromboembolism (VTE) and Risk Factors for Developing VTE in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) in children’s Hospitals-a PHIS Database Study
Authors: Surabhi Batra, Lawrence Salud, Patti Duda, David Bertoch, Reggie Duerst, Matt Hall, Anjali Sharathkumar
Journal: Blood (2014)
Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma.
Authors: Maud Condomines, Dirk Hose, Thierry Reme, John de Vos, Guilhem Requirand, Jean-Francois Rossi, Hartmunt Goldschmidt, Bernard Klein
Journal: Blood (2007)
Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older breast cancer patients.
Authors: Mariana Chavez-Mac Gregor, Ning Zhang, Jiangong Niu, Yufeng Zhang, Linda S. Elting, Thomas A. Buchholz, Vicente Valero, Sharon Hermes Giordano
Journal: Journal of Clinical Oncology (2013)

6630 Background: Adjuvant trastuzumab improves outcomes but is associated with cardiotoxicity. Cardiac monitoring at baseline and at regular intervals during treatment is advised. No data exist on the adequacy of cardiac monitoring in the general population. Of particular interest is the pattern of monitoring in the elderly as they are at increased risk for cardiotoxicity. In a large cohort of trastuzumab-treated patients, we describe the patterns of cardiac monitoring, and evaluate factors associated with suboptimal monitoring. Methods: Breast cancer patients ≥66 years with full Medicare coverage, stage I-III breast cancer diagnosed between 2005-2007, and treated with adjuvant trastuzumab-based chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry-Medicare databases. The frequency of echocardiograms/MUGAs was determined. Baseline monitoring (test in the 4 months prior to initiation of trastuzumab), adequate follow-up monitoring (a test every 4 months during trastuzumab treatment) and optimal monitoring (baseline test and adequate follow-up monitoring) were evaluated. Chemotherapy, trastuzumab use, echo/MUGA, and comorbidities were identified using ICD-9 and HCPCS codes. Prescribing physician characteristics were also evaluated. Descriptive statistics and logistic regression were used. Results: 1221 patients were identified; median age was 71 yrs. Baseline test was not performed in 22% of patients. Suboptimal follow-up monitoring during treatment was observed in 59.5% of the patients. Hispanics were less likely to have baseline test or adequate follow-up monitoring (OR 0.63; 0.4-0.99 and OR 0.60; 0.39-0.93 respectively). Factors associated with optimal cardiac monitoring included anthracycline use (OR 1.8; 1.39-2.36), recent year of diagnosis (OR 1.5; 1.09-2.08); female prescribing physician (OR 1.79; 1.31-2.44) or physician graduated after 1990 (OR 1.45; 1.02-2.06). Conclusions: A large proportion of elderly patients had suboptimal cardiac monitoring. Trastuzumab-related cardiotoxicitiy is reversible and early diagnosis is crucial. Cardiac monitoring should be encouraged, particularly in vulnerable populations.
Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.
Authors: Ujunwa Cynthia Okoye-Okafor, Boris Bartholdy, Bruce Woolcock, Masahiro Kawahara, Tihomira I Todorova, Randy D. Gascoyne, Christian Steidl, Ulrich Steidl
Journal: Blood (2012)
Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously
Authors: Jami le Shammo, Alla Gimelfarb, Wei-Tong Hsu, Irene Dehghan- Paz, Parameswaran Venugopal, Melissa L. Larson, Henry C. Fung, Mohamed Farhat, Amy Rizman, Jerome Loew, Stephanie A. Gregory
Journal: Blood (2008)
Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation.
Authors: Debra Hoppensteadt, Jawed Fareed, Allan Klein, Susan Jasper, Carolyn Apperson-Hansen, Elizabeth Lieber, William Katz, Joseph Malouf, Marcus Stoddard
Journal: Blood (2007)
The Development of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Chronic Myeloid Leukemia (CML), in First Chronic Phase (CP), with HLA Identical Siblings Donors at the Bone Marrow Transplantation Unity–Jau, São Paulo/Brazil and Regional Cooperative Group
Authors: Vergilio Antônio Rensi Colturato, Mair Pedro de Souza, Marcos Augusto Mauad, Wellington Morais de Azevedo, Éderson Roberto de Mattos, Clarisse Martins Machado, Érica R. Pontes, Júlio C. Voltarelli, Belinda Simoes, Eduardo J. A. Paton, Paulo Eduardo de Abreu Machado
Journal: Blood (2008)
Local enema treatment to inhibit FOLH1 /GCPII as a novel therapy for inflammatory bowel disease
Authors: Abhijit A. Date, Rana Rais, Taarika Babu, Jairo Ortiz, Pranjali Kanvinde, Ajit G. Thomas, Sarah C. Zimmermann, Alexandra J. Gadiano, Gilad Halpert, Barbara S. Slusher, Laura M. Ensign
Journal: Journal of Controlled Release (2017)
Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients
Authors: Sylvain Choquet, Shaida Varnous, Claire Deback, Alain Pavie, Véronique Leblond
Journal: Blood (2010)
Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT),
Authors: Jan Cerny, Lesley Woods, Hongbo Yu, Muthalagu Ramanathan, Glen D Raffel, William V Walsh, Laura J Petrillo-Deluca, Natasha M Tarrasky, Elizabeth O'Rourke, Jayde L Bednarik, Bruce Woda, Lloyd Hutchinson, Aimee Kroll, Bruce Barton, Alan G. Rosmarin, Rajneesh Nath
Journal: Blood (2011)
A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.
Authors: Reza Khosravan, Xin Huang, Robin Wiltshire, Mariajose Lechuga, Robert John Motzer
Journal: Journal of Clinical Oncology (2012)

363 Background: Patients requiring sunitinib dose reduction who received a novel dose/schedule modification scheme had longer progression-free survival (PFS) than patients who did not require dose reduction and remained on 50 mg Schedule 4/2 (4 weeks on, 2 weeks off) (Bjarnason 2011). Our analysis compared sunitinib efficacy in advanced RCC patients with/without dose reduction using the label-approved, dose-reduction scheme (ie, 50 mg/37.5 mg/25 mg) and schedule (Schedule 4/2) and explored potential causes of any differences. Methods: Data from a Phase 3 and a Phase 2 trial, sunitinib Schedule 4/2 arms only (N=375 and 146, respectively), were retrospectively analyzed, and pharmacokinetics and baseline characteristics of patients with/without dose reduction compared. Results: In the Phase 3 trial, median (95% CI) PFS was 14.0 (13.1–16.2) months (mos) and 8.1 (6.3–10.6) mos with (n=194) and without (n=181) dose reduction, respectively. In the Phase 2 trial, corresponding PFS values were 13.4 (9.8–19.8) mos and 5.8 (3.9–8.5) mos (n=51 and 95, respectively). In the Phase 2 trial, steady-state mean (SD) total drug trough concentrations were 96.0 (42.2) ng/mL and 85.8 (43.4) ng/mL on Day 29 of Cycle 1 in patients with/without dose reduction, respectively. In both studies, the percent of patients with baseline Memorial Sloan-Kettering Cancer Center risk factors of 0 (favorable), 1–2 (intermediate), and 3 (poor) were 37–47%, 53–57% and 0–6% with dose reduction vs. 25–28%, 65–72%, and 0–10% without dose reduction. The mean (range) time to dose reduction was 7.2 (0.03–40.4) mos in the Phase 3 trial and 4.5 (0.4–22.6) mos in the Phase 2 trial. Conclusions: Patients with dose reduction remaining on Schedule 4/2 appeared to have longer PFS than patients with no dose reduction. The differences were not caused by differences in plasma drug exposures; they appeared to be due, at least in part, to 1) differences in patients’ baseline prognostic factors and 2) patients’ PFS or longevity affecting their dose-reduction status. Thus, efficacy subgroup analysis based on patients’ dose-reduction status appears to be confounded, leading to biased results.
Travel ban threatens medical research and access to care in the US, medical groups warn
Authors: Michael McCarthy
Journal: BMJ (2017)

President Donald Trump’s executive order1 banning nationals from seven Muslim majority nations, as well as all refugees, from entering the county threatens to damage the quality of medical research and healthcare in the US, medical groups and academic centers have warned.

The order bars the entry of all refugees for 120 days and all refugees from Syria indefinitely. The entry of nationals from seven largely Muslim nations—Iran, Iraq, Libya, Somalia, Sudan, Syria, and Yemen—is barred for 90 days. The order was interpreted by the department of homeland security to include holders of “green cards,” who are considered legal residents.

The order, which was issued late in the afternoon and with little warning, caught most travelers unawares. Many had boarded flights to the US before the order was …
Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers
Authors: Kunitoshi Shigeyasu, Shusuke Toden, Timothy J. Zumwalt, Yoshinaga Okugawa, Ajay Goel
Journal: Clinical Cancer Research (2017)

Abstract Cancer has emerged as a leading cause of mortality worldwide, claiming more than 8 million lives annually. Gastrointestinal cancers account for about 35% of these mortalities. Recent advances in diagnostic and treatment strategies have reduced mortality among patients with gastrointestinal cancer, yet a significant number of patients still develop late-stage cancer, where treatment options are inadequate. Emerging interests in “liquid biopsies” have encouraged investigators to identify and develop clinically relevant noninvasive genomic and epigenomic signatures that can be exploited as biomarkers capable of detecting premalignant and early-stage cancers. In this context, microRNAs (miRNA), which are small, noncoding RNAs that are frequently dysregulated in cancers, have emerged as promising entities for such diagnostic purposes. Even though the future looks promising, current approaches for detecting miRNAs in blood and other biofluids remain inadequate. This review summarizes existing efforts to exploit circulating miRNAs as cancer biomarkers and evaluates their potential and challenges as liquid biopsy–based biomarkers for gastrointestinal cancers. Clin Cancer Res; 23(10); 2391–9. ©2017 AACR.
Redirecting cardiac growth mechanisms for therapeutic regeneration
Authors: Ravi Karra, Kenneth D. Poss
Journal: Journal of Clinical Investigation (2017)

Heart failure is a major source of morbidity and mortality. Replacing lost myocardium with new tissue is a major goal of regenerative medicine. Unlike adult mammals, zebrafish and neonatal mice are capable of heart regeneration following cardiac injury. In both contexts, the regenerative program echoes molecular and cellular events that occur during cardiac development and morphogenesis, notably muscle creation through division of cardiomyocytes. Based on studies over the past decade, it is now accepted that the adult mammalian heart undergoes a low grade of cardiomyocyte turnover. Recent data suggest that this cardiomyocyte turnover can be augmented in the adult mammalian heart by redeployment of developmental factors. These findings and others suggest that stimulating endogenous regenerative responses can emerge as a therapeutic strategy for human cardiovascular disease.
Cytokine-Mediated Signaling Is Suppressed in Myeloid Cells and Enhanced in Lymphatic Cells in Patients with Chronic Myeloid Leukemia (CML) — Partial Normalization with Tyrosine Kinase Inhibitors.
Authors: Sari Jalkanen, Satu Mustjoki, Kimmo Porkka, Jukka Vakkila
Journal: Blood (2009)
International Tables of Glycemic Index and Glycemic Load Values: 2008
Authors: Fiona S. Atkinson, Kaye Foster-Powell, Jennie C. Brand-Miller
Journal: Diabetes Care (2008)

To systematically tabulate published and unpublished sources of reliable glycemic index (GI) values.A literature search identified 205 articles published between 1981 and 2007. Unpublished data were also included where the data quality could be verified. The data were separated into two lists: the first representing more precise data derived from testing healthy subjects and the second primarily from individuals with impaired glucose metabolism.The tables, which are available in the online-only appendix, list the GI of over 2,480 individual food items. Dairy products, legumes, and fruits were found to have a low GI. Breads, breakfast cereals, and rice, including whole grain, were available in both high and low GI versions. The correlation coefficient for 20 staple foods tested in both healthy and diabetic subjects was r = 0.94 (P < 0.001).These tables improve the quality and quantity of GI data available for research and clinical practice.
Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.
Authors: Hideto Matsui, Masaru Shibata, Brian Brown, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Robert P. Hebbel, Jacques Galipeau, Christine Hough, David Lillicrap
Journal: Blood (2006)
Pre-Clincial Evaluation of a Novel Purine Analogue 8-NH2-Adenosine in Mantle Cell Lymphoma Indicates Efficacy Via Alterations in RNA/DNA Synthesis and Cellular Bioenergetics
Authors: Mala Shanmugam, Jennifer Dennison, Jun Qian, Varsha Gandhi, Mary Ayres, Amareshwar Singh, Samuel McBrayer, Carter Neugarten, Priya Shanmugam, Karthik Singh, Leo I. Gordon, Nancy Krett, Steven T. Rosen
Journal: Blood (2008)
Tumor-homing cytotoxic human induced neural stem cells for cancer therapy
Authors: Juli R. Bagó, Onyi Okolie, Raluca Dumitru, Matthew G. Ewend, Joel S. Parker, Ryan Vander Werff, T. Michael Underhill, Ralf S. Schmid, C. Ryan Miller, Shawn D. Hingtgen
Journal: Science Translational Medicine (2017)

Human skin cells directly converted to induced neural stem cells seek out cancer foci and deliver therapeutic agents that inhibit glioblastoma progression.
Heavy ethanol intake and elevated prostate cancer risk among men with previous negative biopsies in the REDUCE trial.
Authors: Lionel Lloyds Banez, Cathrine Hoyo, Leah Gerber, Daniel M. Moreira, Madeline G McKeever, Gerald L. Andriole, Stephen J. Freedland
Journal: Journal of Clinical Oncology (2012)

187 Background: Whether ethanol intake contributes to prostate cancer (CaP) risk is debated. Although ethanol was found to contribute to increased CaP risk in the Prostate Cancer Prevention Trial, whether ethanol intake impacts CaP risk among men with previous negative biopsies has not been previously assessed. We therefore examined the relationship between ethanol consumption and CaP risk in the REDUCE trial and further sought to determine whether ethanol intake modifies the effect of dutasteride in reducing CaP risk. Methods: This is secondary analyses using data from 6,729 men who had at least one on-study biopsy while participating in the REDUCE trial. Ethanol intake, which was expressed as units (½ pint of beer or 1 glass of wine, etc.) per week, was analyzed as a continuous and three-tiered categorical variable [non-drinker, moderate (≤7 units/week), heavy-drinker (&gt;7 units/week)]. Risks for overall and high-grade (Gleason ≥7 vs. Gleason&lt;7 CaP or biopsy negative) CaP were evaluated using logistic regression adjusting for clinical parameters including dutasteride intake. Test for interaction was used to determine whether the association between dutasteride and CaP risk is influenced by ethanol. Results: Forty-nine percent were moderate-drinkers and 26% were heavy-drinkers. On a continuum, increased ethanol intake was significantly associated with elevated risk for overall (p=0.035) and high-grade CaP (p=0.048). Compared to non-drinkers, heavy drinkers were at increased risk for overall (OR 1.21; 95% CI 1.02-1.43; p=0.03) and high-grade CaP (OR 1.34; 95% CI 1.01-1.78; p=0.04). Risks for overall (p=0.55) and high-grade CaP (p=0.21) were comparable between moderate- and non-drinkers. Dutasteride reduced overall CaP risk (OR 0.73; p&lt;0.001) and ethanol intake did not modify the effect of dutasteride on CaP incidence (p-interaction=0.64). Conclusions: Among low-risk men with at least one prior negative prostate biopsy, heavy ethanol intake is associated with increased risk for overall and high-grade CaP. In contrast to CaP prevention with finasteride, which appears to be inhibited by heavy ethanol intake, consumption of ethanol does not negatively impact CaP prevention with dutasteride.
Lipid Peroxidation Products In Bone Marrow Plasma (BMp) and Peripheral Blood Plasma (PBp) From Patients with Low Risk Myelodysplastic Syndrome (MDS)
Authors: Leonardo Julio Feldman, Edgardo Rodriguez, Aldo Sansinanea, Vera Milovic, Gregorio Jaimovich, Guillermo Drelichman, Juan Real, Dolores Puente, Alejandro Requejo
Journal: Blood (2010)
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Authors: Matthew B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Brian A. Allen, Hajime Uno, Jason L. Hornick, Chinedu I. Ukaegbu, Lauren K. Brais, Philip G. McNamara, Robert J. Mayer, Deborah Schrag, Jeffrey A. Meyerhardt, Kimmie Ng, John Kidd, Nanda Singh, Anne-Renee Hartman, Richard J. Wenstrup, Sapna Syngal
Journal: Journal of Clinical Oncology (2017)

Purpose Hereditary factors play an important role in colorectal cancer (CRC) risk, yet the prevalence of germline cancer susceptibility gene mutations in patients with CRC unselected for high-risk features (eg, early age at diagnosis, personal/family history of cancer or polyps, tumor microsatellite instability [MSI], mismatch repair [MMR] deficiency) is unknown. Patients and Methods We recruited 1,058 participants who received CRC care in a clinic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR results. All participants underwent germline testing for mutations in 25 genes associated with inherited cancer risk. Each gene was categorized as high penetrance or moderate penetrance on the basis of published estimates of the lifetime cancer risks conferred by pathogenic germline mutations in that gene. Results One hundred five (9.9%; 95% CI, 8.2% to 11.9%) of 1,058 participants carried one or more pathogenic mutations, including 33 (3.1%) with Lynch syndrome (LS). Twenty-eight (96.6%) of 29 available LS CRCs demonstrated abnormal MSI/MMR results. Seventy-four (7.0%) of 1,058 participants carried non-LS gene mutations, including 23 (2.2%) with mutations in high-penetrance genes (five APC, three biallelic MUTYH, 11 BRCA1/2, two PALB2, one CDKN2A, and one TP53), 15 of whom lacked clinical histories suggestive of their underlying mutation. Thirty-eight (3.6%) participants had moderate-penetrance CRC risk gene mutations (19 monoallelic MUTYH, 17 APC*I1307K, two CHEK2). Neither proband age at CRC diagnosis, family history of CRC, nor personal history of other cancers significantly predicted the presence of pathogenic mutations in non-LS genes. Conclusion Germline cancer susceptibility gene mutations are carried by 9.9% of patients with CRC. MSI/MMR testing reliably identifies LS probands, although 7.0% of patients with CRC carry non-LS mutations, including 1.0% with BRCA1/2 mutations.
Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors.
Authors: Albert C. Lockhart, Shankar Sundaram, John Sarantopoulos, Monica M. Mita, Alex R. Lane, Jennifer L. Moseley, Jean-Francois Dedieu, Diane Stash, Xin Zhi, Florent Mazuir, Alain C. Mita
Journal: Journal of Clinical Oncology (2012)

162 Background: Cabazitaxel (Cbz) is a novel taxane with broad in vivo efficacy in taxane-sensitive and -resistant tumors. Clinical activity of Cbz was confirmed in the Phase III TROPIC trial ( NCT00417079 ); Cbz significantly improved overall survival compared with mitoxantrone in patients (pts) with metastatic castration-resistant prostate cancer whose disease had progressed during or after a prior docetaxel-containing regimen. Therapeutic synergism of Cbz/cisplatin (Cis) has been demonstrated in tumor-bearing mice. Methods: The primary objective in part 1 of this Phase I study ( NCT00925743 ) was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of Cbz/Cis. Secondary objectives were safety, pharmacokinetics (PK) and efficacy. The primary objective of part 2 was to determine the antitumor activity at the MTD. Eligible pts were ≥ 18 yrs, ECOG PS ≤ 1, with confirmed metastatic or unresectable solid tumors for which Cis therapy was considered appropriate. A 3 + 3 dose escalation with a starting dose (level 0) of 20/75 mg/m 2 (Cbz/Cis), administered IV Q3W, was used. The MTD was the highest dose at which 0/3 or ≤ 1/6 pts experienced a DLT in Cycle 1. Results: Pts (N = 25; 10 in part 1; 15 in part 2) with a median age of 56 yrs were enrolled. The most frequent primary tumors were lung (n = 4), prostate, ovary and pancreas (each n = 2). 2 of 6 evaluable pts experienced a DLT at dose level 0 (Grade 3 acute renal failure; febrile neutropenia). The MTD was 15/75 mg/m 2 as no DLTs were observed. Eighteen pts were treated at the MTD and 60 cycles were administered (median = 3; range 1–8). The most frequent non-hematologic treatment-related adverse events (all Grade/Grade 3–4) were nausea (78%/22%), vomiting (72%/11%), fatigue (61%/17%), anorexia (67%/11%) and diarrhea (44%/0%). Incidence of Grade 3–4 neutropenia was 78% and 1 pt had febrile neutropenia. No PK interactions between Cbz and Cis were observed. Stable disease was seen in 11 pts. No objective responses were reported. Conclusions: The MTD of Cbz/Cis was 15/75 mg/m 2 . The combination had a manageable safety profile consistent with that of a platinum/taxane combination. No PK interactions were seen. Further investigations into the combined treatment combination are planned.
Single-Institute Comparable Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated and Related Donor in Patients with Myeloid Malignancies.
Authors: Shingo Yano, Noriko Usui, Nobuaki Dobashi, Yutaka Takei, Yuichi Yahagi, Shinobu Takahara, Hiroko Otsubo, Yuko Yamaguchi, Kinuyo Kasama, Jiro Minami, Tatsunosuke Kobayashi, Yasutaka Hoshi, Tadashi Kobayashi, Osamu Asai, Keisuke Aiba
Journal: Blood (2007)
Smoothened (SMO), a G-Protein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma,
Authors: Changju Qu, Yadong Liu, Kranthi Kunkalla, Nitin K Agarwal, Estelle Bourbon, Lan V Pham, Richard J. Ford, Rajesh Singh, Francisco Vega
Journal: Blood (2011)
ブタ冠動脈において血清中コルチゾール濃度の持続上昇はRhoキナーゼ経路を介して冠動脈過剰収縮の原因となる(Sustained Elevation of Serum Cortisol Concentration Causes Hypercontraction of Porcine Coronary Arteries through Rho-kinase Pathway)
Authors: Hizume Takatoshi, Morikawa Keiko, Takaki Aya, Abe Kotaro, Sunagawa Kenji, Shimokawa Hiroaki
Journal: Circulation (2006)